SQZ Biotechnologies Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$226.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • SQZ Biotechnologies's estimated annual revenue is currently $17.2M per year.(i)
  • SQZ Biotechnologies received $72.0M in venture funding in August 2018.
  • SQZ Biotechnologies's estimated revenue per employee is $118,014
  • SQZ Biotechnologies's total funding is $226.4M.
  • SQZ Biotechnologies's current valuation is $228.7M. (January 2022}

Employee Data

  • SQZ Biotechnologies has 146 Employees.(i)
  • SQZ Biotechnologies grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

SQZ Biotech is a unique cell therapy company, utilizing the proprietary CellSqueeze® platform to develop a new generation of cell therapies. SQZ currently focuses on the development of novel treatments that leverage targeted immune modulation to impact oncology and autoimmune diseases. SQZ: Empower cells to change lives.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$226.4M

Total Funding

146

Number of Employees

$17.2M

Revenue (est)

11%

Employee Growth %

$228.7M

Valuation

N/A

Accelerator

SQZ Biotechnologies News

2020-05-18 - SQZ Biotech Closes $65 Million Series D Financing

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the completion of a $65 million Series D preferred stock financing. The round was led by Temasek with parti ...

2020-05-18 - SQZ Biotech snags $65M to push cancer vaccine, break into infectious disease

SQZ Biotech is looking to propel its lead asset, a cancer vaccine for HPV-positive tumors, through phase 1 and expand its cell-squeezing technology beyond oncology into infectious diseases. And it's reeled in $65 million to do it. Sponsored by Agilent Technologies How would you like to win fre ...

2021-09-13 - SQZ BIOTECHNOLOGIES CO : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure. On September 13, 2021, SQZ Biotechnologies Company (the "Company") issued a press release titled "SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform." A copy of the press release is attached hereto ...

09/03/2019 - Merck's head of IR departs to take up finance chief role at SQZ ...

Teri Loxam is leaving her role as head of IR at Merck to become the chief financial officer at SQZ Biotechnologies, a private firm focused on ...

06/25/2019 - Erytech Pharma SA bags US$57m from SQZ Biotechnologies

Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to ... Erytech will licence the rights to use its ERYCAPS platform to SQZ, which ...

09/03/2019 - SQZ Biotech Announces Appointment of Experienced ...

SQZ Biotech Announces Appointment of Experienced Pharmaceutical Executive Teri Loxam as Chief Financial Officer ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$53M1469%N/A
#2
$29.3M148N/AN/A
#3
$23.3M15014%$163.3M
#4
$34M15019%$423.8M
#5
$45.7M15420%N/A

SQZ Biotechnologies Funding

DateAmountRoundLead InvestorsReference
2015-06-25$5.0MAPolaris PartnersArticle
2016-10-03$16.0MUndisclosedNanoDimensionArticle
2016-12-05$4.0MBQuark Venture IncArticle
2017-12-06$UndisclosedUndisclosedJDRF T1D Fund.Article
2018-08-09$72.0MCMultipleArticle